Nkarta signs its name to an ambitious future with manufacturing hub for not one but multiple marketed drugs

Kyle Blankenship

Riding science out of Dario Campana’s famed lab in Singapore, West Coast biotech Nkarta has been a high-profile entry into the race for the industry’ …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Nkarta signs its name to an ambitious future with manufacturing hub for not one but multiple marketed drugs

Kyle Blankenship

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Nkar­ta signs its name to an am­bi­tious fu­ture with man­u­fac­tur­ing hub for not one but mul­ti­ple mar­ket­ed drugs

Kyle Blankenship

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nkarta signs its name to an ambitious future with manufacturing hub for not one but multiple marketed drugs

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Norbert Bischofberger's time as Kronos CEO ends as biotech seeks new life

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy